Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2049
Source ID: NCT00673894
Associated Drug: Sitagliptin
Title: Effects of Glutamine on GLP-1 and Insulin Secretion in Man
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00673894/results
Conditions: Type 2 Diabetes
Interventions: DRUG: Sitagliptin|DRUG: Placebo
Outcome Measures: Primary: Postprandial Glucose Area Under the Curve (AUC), The area under the curve (AUC) of the postprandial glucose following a meal challenge, 0 to 180 minutes | Secondary: Fructosamine, The blood concentration of the glycemic control marker fructosamine, 4 weeks
Sponsor/Collaborators: Sponsor: Garvan Institute of Medical Research
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 22
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2008-04
Completion Date: 2014-11
Results First Posted: 2019-05-13
Last Update Posted: 2019-05-13
Locations: Clinical Research Facility, Sydney, New South Wales, 2010, Australia
URL: https://clinicaltrials.gov/show/NCT00673894